{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["114(3)"],"submitter":["Moreno R"],"funding":["Daiichi Sankyo, Inc"],"pubmed_abstract":["<h4>Background</h4>Patients with atrial fibrillation (AF) and a recent (≤ 90 days) percutaneous coronary intervention (PCI) undergoing transcatheter aortic valve implantation (TAVI) are at high bleeding risk due to the addition of oral antiplatelet (OAP) agents on top of oral anticoagulants. Data on outcomes of these patients are needed to optimize antithrombotic treatment.<h4>Methods</h4>This analysis compared annualized clinical event rates in patients with and without a recent PCI enrolled in ENVISAGE-TAVI AF, a prospective, randomized, open-label, adjudicator-masked trial comparing edoxaban and vitamin K antagonists in AF patients after TAVI. The primary efficacy and safety outcomes were net adverse clinical events (NACE) and major bleeding.<h4>Results</h4>Overall, 132 (94.3%) patients"],"journal":["Clinical research in cardiology : official journal of the German Cardiac Society"],"pagination":["313-322"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11914355"],"repository":["biostudies-literature"],"pubmed_title":["Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the ENVISAGE-TAVI AF trial."],"pmcid":["PMC11914355"],"pubmed_authors":["Moreno R","Souza J","Unverdorben M","Ohlmann P","Mollmann H","Hengstenberg C","Smolnik R","Valgimigli M","Dangas G","Van Mieghem NM","Jin J","Nombela-Franco L"],"additional_accession":[]},"is_claimable":false,"name":"Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the ENVISAGE-TAVI AF trial.","description":"<h4>Background</h4>Patients with atrial fibrillation (AF) and a recent (≤ 90 days) percutaneous coronary intervention (PCI) undergoing transcatheter aortic valve implantation (TAVI) are at high bleeding risk due to the addition of oral antiplatelet (OAP) agents on top of oral anticoagulants. Data on outcomes of these patients are needed to optimize antithrombotic treatment.<h4>Methods</h4>This analysis compared annualized clinical event rates in patients with and without a recent PCI enrolled in ENVISAGE-TAVI AF, a prospective, randomized, open-label, adjudicator-masked trial comparing edoxaban and vitamin K antagonists in AF patients after TAVI. The primary efficacy and safety outcomes were net adverse clinical events (NACE) and major bleeding.<h4>Results</h4>Overall, 132 (94.3%) patients","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-06-01T22:56:15.629Z","creation":"2025-04-06T10:50:17.864Z"},"accession":"S-EPMC11914355","cross_references":{"pubmed":["38294497"],"doi":["10.1007/s00392-024-02379-5"]}}